8GKK

Crystal Structure of the Humanized MUC16 Specific Antibody huAR9.6

8GKK の概要

• エントリーDOI: 10.2210/pdb8gkk/pdb
• 関連するPDBエントリー: 8GKJ
• 分子名称: MUC16 antibody AR9.6 heavy chain, MUC16 antibody AR9.6 light chain, SULFATE ION, ... (4 entities in total)
• 機能のキーワード: fab, ca125, immune system
• 由来する生物種: Homo sapiens (human); 詳細
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 47738.97

構造登録者

Brooks, C.L.,Murray, B. (登録日: 2023-03-19, 公開日: 2024-03-20, 最終更新日: 2024-10-23)

主引用文献

Aguilar, E.N.,Sagar, S.,Murray, B.R.,Rajesh, C.,Lei, E.K.,Michaud, S.A.,Goodlett, D.R.,Caffrey, T.C.,Grandgenett, P.M.,Swanson, B.,Brooks, T.M.,Black, A.R.,van Faassen, H.,Hussack, G.,Henry, K.A.,Hollingsworth, M.A.,Brooks, C.L.,Radhakrishnan, P.
Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6.
Mol.Cancer Ther., 23:836-853, 2024

PubMed Abstract: Mucin-16 (MUC16) is a target for antibody-mediated immunotherapy in pancreatic ductal adenocarcinoma (PDAC) among other malignancies. The MUC16-specific monoclonal antibody AR9.6 has shown promise for PDAC immunotherapy and imaging. Here, we report the structural and biological characterization of the humanized AR9.6 antibody (huAR9.6). The structure of huAR9.6 was determined in complex with a MUC16 SEA (Sea urchin sperm, Enterokinase, Agrin) domain. Binding of huAR9.6 to recombinant, shed, and cell-surface MUC16 was characterized, and anti-PDAC activity was evaluated in vitro and in vivo. HuAR9.6 bound a discontinuous, SEA domain epitope with an overall affinity of 88 nmol/L. Binding affinity depended on the specific SEA domain(s) present, and glycosylation modestly enhanced affinity driven by favorable entropy and enthalpy and via distinct transition state thermodynamic pathways. Treatment with huAR9.6 reduced the in vitro growth, migration, invasion, and clonogenicity of MUC16-positive PDAC cells and patient-derived organoids (PDO). HuAR9.6 blocked MUC16-mediated ErbB and AKT activation in PDAC cells, PDOs, and patient-derived xenografts and induced antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. More importantly, huAR9.6 treatment caused substantial PDAC regression in subcutaneous and orthotopic tumor models. The mechanism of action of huAR9.6 may depend on dense avid binding to homologous SEA domains on MUC16. The results of this study validate the translational therapeutic potential of huAR9.6 against MUC16-positive PDACs.

PubMed: 38394685
DOI: 10.1158/1535-7163.MCT-23-0868

実験手法

X-RAY DIFFRACTION (1.75 Å)